Marksans Pharma Ltd. (NSE: MARKSANS, BSE: 524404) is a Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹13,892 Cr, it ranks #485 by market cap among the 6,197 Indian listed companies on FinBizNet, and #11 of 63 in Pharmaceuticals. At ₹316.80 (as of 16 Nov 2026), the share price is 9.7% below its 52-week high of ₹350.95 and 104.4% above its 52-week low of ₹155.00. The share price is up 74.1% over one year and up 5.0% over three months.
| Current Price | ₹316.80 |
|---|---|
| Market Cap | ₹13,892 Cr |
| NSE Symbol | MARKSANS |
| BSE Code | 524404 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 35 |
| Return on Equity | 25.45% |
| Return on Assets | 8.85% |
| 52-Week Range | ₹155.00 – ₹350.95 |
| 1-Year Price Change | +74.1% |
| 3-Month Price Change | +5.0% |
| Beta (1Y) | 0.69 |
| Dividend Yield | 0.28% |
| Headquarters | Mumbai, Maharashtra |
| Website | marksanspharma.com |
| Revenue | ₹940 Cr |
|---|---|
| Net Profit | ₹144 Cr |
| Net Margin | 15.3% |
| EPS (Basic) | ₹3.12 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Marksans Pharma Ltd. reported revenue of ₹940 Cr in Q2 FY27, up 30.5% from ₹720 Cr in Q2 FY26 and up 11.8% from ₹841 Cr in Q1 FY27. It posted a net profit of ₹144 Cr for the quarter, against a net profit of ₹99 Cr in Q2 FY26 (up 44.8%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹71 Cr (Q4 FY25) to ₹940 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹940 Cr | ₹144 Cr | 15.3% |
| Q1 FY27 | ₹841 Cr | ₹159 Cr | 19.0% |
| Q4 FY26 | ₹856 Cr | ₹149 Cr | 17.4% |
| Q3 FY26 | ₹754 Cr | ₹114 Cr | 15.1% |
| Q2 FY26 | ₹720 Cr | ₹99 Cr | 13.8% |
| Q1 FY26 | ₹620 Cr | ₹58 Cr | 9.4% |
| Q4 FY25 | ₹71 Cr | ₹9 Cr | 12.8% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 43.87% of Marksans Pharma Ltd.'s shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 44.7% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
1. Bulk Drugs Division-This segment engages in manufacturing pharmaceutical formulations. 2. Formulations Division-This segment engages in the manufacture and sale of bulk drugs. 3. Research, Manufacturing and Marketing of Pharmaceutical Formulation-This segment engages in the manufacture and sale of formulations and active pharmaceutical ingredients.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Marksans Pharma Ltd. | ₹13,892 Cr | 35 | 25.45% | ₹940 Cr | +74.1% |
Listed by market capitalisation. Ratios are shown for context only.
Marksans Pharma Ltd. is trading at ₹316.80, with a market capitalisation of ₹13,892 Cr.
Marksans Pharma Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Marksans Pharma Ltd. has a P/E of 35 and a return on equity of 25.45%.
Marksans Pharma Ltd. is listed on the NSE under the symbol MARKSANS and on the BSE under the scrip code 524404.
Marksans Pharma Ltd.'s share price is up 74.1% over one year and up 5.0% over three months. Its 52-week range is ₹155.00 to ₹350.95.
In Q2 FY27, Marksans Pharma Ltd. reported revenue of ₹940 Cr and net profit of ₹144 Cr, with basic EPS of ₹3.12 (consolidated, parsed from the company's exchange filing).
Marksans Pharma Ltd. reported revenue of ₹940 Cr in Q2 FY27, up 30.5% from ₹720 Cr in Q2 FY26 and up 11.8% from ₹841 Cr in Q1 FY27.
Promoters held 43.87% of Marksans Pharma Ltd.'s shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.